Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03346772 · ClinicalTrials.gov registry record · Phase 4

Study of Immune Responses to Influenza Vaccination

A Phase 4 study of Influenza Vaccination, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 4
Development phase
75
Enrollment target
1
Study location

NCT03346772 is a Phase 4 study of Influenza Vaccination that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 75 participants, below the 37,849-participant average among 3 other Influenza Vaccination trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03346772, a Phase 4 study of Influenza Vaccination, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 4
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.

Conditions Studied

Interventions

  • BIOLOGICAL Influenza vaccination

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2017-10-20
Est. Completion 2026-07-01
Phase Phase 4

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT03346772

The ClinicalTrials.gov registry entry for NCT03346772 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37,849-participant average among 3 other Influenza Vaccination trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza Vaccination appearing as the primary indexed condition, and to 1 intervention - of which Influenza vaccination is the first listed.

NCT03346772 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03346772 about?

NCT03346772 is a clinical study titled "Study of Immune Responses to Influenza Vaccination". Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.

What is the current status of trial NCT03346772?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2017-10-20. Estimated completion is 2026-07-01.

What conditions does trial NCT03346772 study?

This clinical trial studies the following conditions: Influenza Vaccination.

What interventions are being tested in trial NCT03346772?

The interventions under investigation include: Influenza vaccination (BIOLOGICAL).

Who is sponsoring clinical trial NCT03346772?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03346772 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza Vaccination

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.